Shilpa Medicare profit and loss

Latest FY26

Revenue: ₹1,539cr+19.6% on FY25
EBITDA: ₹435cr+37.1% on FY25
Net profit: ₹243cr+210.8% on FY25
EPS: ₹12.44+54.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	1,682	1,539	1,286	1,152	1,050	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	7.4	9.8	23.2	8.2	17.4
	1,690	1,549	1,310	1,160	1,068
	500	471	350	424	369
	29.9	25.6	22.5	18.0	33.8
	−14.5	−36.2	37.6	−34.8	13.3
	353	335	293	281	287
	52.1	58.8	75.5	91.8	58.7
	126	120	113	108	95.5
	335	309	266	218	245
	1,382	1,283	1,158	1,107	1,102
	479	435	317	244	102
	353	315	204	137	6.8
Profit
	308	266	152	53.0	−34.5
	30.5	29.3	−28.1	6.1	0.0
	338	295	124	59.1	−34.5
	61.7	46.7	73.3	45.3	34.1
	−15.2	5.3	−29.3	−22.9	−41.5
	46.5	52.0	44.0	22.4	−7.4
	5.5	0.0	−1.3	−4.9	−5.4
	297	243	78.3	31.9	−32.5
	292	243	79.6	36.7	−27.1
	4.2	0.0	−2.3	−2.4	3.2
	301	243	76.0	29.5	−29.2
	—	—	78.3	31.9	−32.5
	—	—	−0.0	0.0	1.6
Per share
	₹15.28	₹12.44	₹8.04	₹3.67	₹3.74
	₹15.28	₹12.44	₹8.04	₹3.67	₹3.74
Other comprehensive income — detail
	—	—	−2.3	—	—
	—	—	−2.3	−3.5	—
	—	—	—	−1.1	—
Per share — as-filed variants
	₹15.28	₹12.44	₹8.04	₹3.67	₹3.74
	₹15.28	₹12.44	₹8.04	₹3.67	₹3.74
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,167	1,078	876	744	634
	69.3%	70.1%	68.1%	64.6%	60.4%
Adjusted (ex-exceptional items) — derived
	308	266	152	53.0	−34.5
	30.5	29.3	−28.1	6.1	0.0
	271	219	96.4	28.1	−32.5
	₹13.93	₹11.21	₹9.90	₹3.23	₹3.74

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SHILPAMED₹935.60

Shilpa Medicare Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersNATCOPHARM SPARC STAR RUBICON SUPRIYA THYROCARE VIYASH PARKHOSPSMcap ₹18,300 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,050.1	1,151.6	1,286.4	1,538.9	1,682.5
Other Income	17.4	8.2	23.2	9.8	7.4
Total Income	1,067.5	1,159.8	1,309.6	1,548.7	1,689.8
Expenses
+ Cost of Materials Consumed	368.8	424.3	350.3	471.0	500.5
+ Purchases of Stock-in-Trade	33.8	18.0	22.5	25.6	29.9
+ Changes in Inventories	13.3	-34.8	37.6	-36.2	-14.5
+ Employee Benefit Expense	287.3	281.5	292.7	334.9	352.8
+ Finance Costs	58.7	91.8	75.5	58.8	52.1
+ Depreciation & Amortisation	95.5	107.9	113.0	119.7	126.0
+ Other Expenses	244.6	218.1	266.3	308.9	335.2
Total Expenses	1,102.0	1,106.8	1,157.9	1,282.7	1,382.0
EBITDA	102.3	244.5	317.0	434.7	478.6
EBIT	6.8	136.6	204.1	315.0	352.5
Profit
PBT before Exceptional Items	-34.5	53.0	151.7	266.0	307.8
+ Exceptional Items	0.0	6.1	-28.1	29.3	30.5
Pretax Income	-34.5	59.1	123.6	295.3	338.3
+ Current Tax	34.1	45.3	73.3	46.7	61.7
+ Deferred Tax	-41.5	-22.9	-29.3	5.3	-15.2
Tax Expense	-7.4	22.4	44.0	52.0	46.5
+ Share of Associates & JVs	-5.4	-4.9	-1.3	0.0	5.5
Net Income	-32.5	31.9	78.3	243.3	297.3
+ Net Income — Continuing Ops	-27.1	36.7	79.6	243.3	291.8
+ Other Comprehensive Income	3.2	-2.4	-2.3	0.0	4.2
Total Comprehensive Income	-29.2	29.5	76.0	243.3	301.5
Net Income to Common	-32.5	31.9	78.3	—	—
Minority Interest	1.6	0.0	-0.0	—	—
Per Share
Basic EPS	3.74	3.67	8.04	12.44	15.28
Diluted EPS	3.74	3.67	8.04	12.44	15.28
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-2.3	—	—
+ Items NOT to be Reclassified to P&L	—	-3.5	-2.3	—	—
+ Tax on Items NOT to be Reclassified — alt tag	—	-1.1	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.74	3.67	8.04	12.44	15.28
Diluted EPS — Continuing Operations	3.74	3.67	8.04	12.44	15.28
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	634.2	744.0	876.0	1,078.5	1,166.5
Gross Margin %	60.39	64.61	68.10	70.08	69.33
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-34.5	53.0	151.7	266.0	307.8
− Exceptional Items (reconciliation)	0.0	6.1	-28.1	29.3	30.5
Net Income Adj (tax-effected)	-32.5	28.1	96.4	219.2	271.0
EPS Adj	3.74	3.23	9.90	11.21	13.93
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	—
Paid Up Equity Capital	8.7	8.7	9.8	19.6	19.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.